Arakis Ltd. raised £29 million (US$52 million) in its third funding round, providing enough money to take the company to 2007 and allowing it to start U.S. and European Phase III trials of AD 923 in cancer breakthrough pain.
Arakis Ltd. raised £29 million (US$52 million) in its third funding round, providing enough money to take the company to 2007 and allowing it to start U.S. and European Phase III trials of AD 923 in cancer breakthrough pain.
